Lutetium-177 rhPSMA10.1 - AVEO Oncology
Alternative Names: 177Lu-rhPSMA10.1 - AVEO OncologyLatest Information Update: 09 Apr 2024
At a glance
- Originator AVEO Oncology
- Class Antineoplastics; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Prostate cancer
Highest Development Phases
- Phase I/II Prostate cancer
Most Recent Events
- 29 Mar 2024 Phase-I/II clinical trials in Prostate cancer (Diagnosis) in USA (IV) (NCT06066437)
- 20 Oct 2023 Lutetium-177 rhPSMA10.1 - AVEO Pharmaceuticals is available for licensing as of 20 Oct 2023. https://www.aveooncology.com/about/partnerships/
- 11 Oct 2023 Preclinical trials in Prostate cancer (Diagnosis) in USA (IV) (NCT06066437)